Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias

Haematologica

Volumn 93, Issue 9, 2008, Pages 1385-1388

  Di Tucci, Anna Angela ^a   Matta, Gildo ^b   Deplano, Simona ^a   Gabbas, Attilio ^c   Depau, Cristina ^a   Derudas, Daniele ^a   Caocci, Giovanni ^d   Agus, Annalisa ^e   Angelucci, Emanuele ^a  

^a Ospedale Oncologico A Businco   (Italy)

^b BROTZU HOSPITAL   (Italy)

^c Ematologia Ospedale di Nuoro   (Italy)

^d Binaghi Hospital   (Italy)

^e Osp Regionale per le Microcitemie   (Italy)

Author keywords

Cardiac iron; Magnetic resonance imaging; Myelodysplastic syndromes; T2*

Indexed keywords

DEFEROXAMINE;

AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE CONCENTRATE; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; MALE; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYOCARDIAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING;

AGED; AGED, 80 AND OVER; ANEMIA; BLOOD TRANSFUSION; FEMALE; HUMANS; IRON; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 51049118552     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12759     Document Type: Article

References (20)

1. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9.
2. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-7.
3. Konen E, Ghoti H, Goitein O, Winder A, Kushnir T, Eshet Y, et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique. Am J Hematol 2007;82:1013-6.
4. Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw 2006;4:91-6.
5. Chacko J, Pennell DJ, Tanner MA, Hamblin TJ, Wonke B, Levy T, et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 2007;138:587-93.
6. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003;101:4632-9.
7. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
8. Mesa RA, Verstovsek S, Cervantes F Barosi G, Reilly JT, Dupriez B, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res 2007;31:737-40.
9. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002;87:1286-306.
10. Porter JB. Practical management of iron overload. Br J Haematol 2001;115:239-52.
11. Westwood MA, Firmin DN, Gildo M, Renzo G, Stathis G, Markissia K, et al. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging 2005;21:531-8.
12. Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ. Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica 2006;91:1388-91.
13. Pennell DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci 2005;1054:373-8.
14. Jelali MA, Luciani A, Kobeiter H, Zafrani S, Anglade MC, Zegai B, et al. MRI features of intrahepatic extramedullary haematopoiesis in sickle cell anaemia. Cancer Imaging 2006;6:182-5.
15. Wong Y, Chen F, Tai KS, Yip LK, Tsang KW, Chan FL, et al. Imaging features of focal intrahepatic extramedullary haematopoiesis. Br J Radiol 1999;72:906-10.
16. Beutler E, Barton JC, Felitti VJ, Gelbart T, West C, Lee PL, et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 2003;31:305-9.
17. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10.
18. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-603.
19. Mavrogeni SI, Markussis V, Kaklamanis L, Tsiapras D, Paraskevaidis I, Karavolias G, et al. A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur J Haematol 2005;75:241-7.
20. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med 1971;51:209-21.